Fig. 3.

Expression analysis of miR-29b in 107 CLL patients. (A) The expression of miR-29b in CLL patients with respect to IGHV mutational status and TP53 aberrations. (B and C) The effect of variations detected in pri-miR-29b in separated groups of patients based on IGHV status (48 mut IGHV, 52 unmut IGHV); patients with the TP53 mutation/deletion (n = 6) were excluded (4 patients unmut IGHV, 2 patients mut IGHV).

Not determined (ND): IGHV status is not known; *Indicates major allele of the particular SNP or wt pri-miR-29b-2; ^#Indicates minor allele of the particular SNP or novel variation detected in pri-miR-29b-2.